Gfra1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox gene
|name=GDNF Family Receptor Alpha 1
|symbol=GFRA1
|alias=GFRα1, GDNFR-α1, RETL1, GDNFRA
|chromosome=10
|location=10q25.3
|gene_id=3914
|omim=601924
|ensembl=ENSG00000151892
|uniprot=P56159
|diseases=Parkinson's Disease, Hirschsprung Disease, Congenital Megacolon, Multiple System Atrophy, Peripheral Neuropathy
}}
The GFRA1 gene encodes the GDNF family receptor alpha 1 (GFRα1), which serves as the primary high-affinity receptor for glial cell line-derived neurotrophic factor (GDNF). GFRα1 is a GPI-anchored protein that plays essential roles in the development, survival, and maintenance of dopaminergic neurons, enteric neurons, and various peripheral neuronal populations[1][2].
The GFRA1 gene is located on chromosome 10q25.3 and spans approximately 54 kb of genomic DNA. The gene consists of 20 exons that undergo alternative splicing to generate multiple protein isoforms with distinct expression patterns and signaling properties[3].
GFRα1 is a 464 amino acid protein with distinct structural features:
| Domain | Position | Function |
|---|---|---|
| N-terminal signal peptide | 1-21 | Secretory pathway targeting |
| Leucine-rich repeat (LRR) | 22-200 | Ligand binding |
| N-terminal domain (NTD) | 201-350 | Dimerization, GDNF binding |
| GPI anchor signal | 430-464 | Membrane attachment |
GFRα1 mediates GDNF signaling through two primary mechanisms[4][5]:
RET-Dependent Signaling
RET-Independent Signaling
| Complex | Components | Signaling Outcome |
|---|---|---|
| GDNF/GFRα1/RET | Full tripartite complex | Potent survival signaling |
| GDNF/GFRα1 | Soluble complex | RET-independent effects |
| GFRα1 clusters | Lipid rafts | Enhanced signaling |
GFRα1 shows distinctive expression in:
| Brain Region | Expression | Functional Significance |
|---|---|---|
| Substantia Nigra pars compacta | Very High | Dopaminergic neuron survival |
| Ventral Tegmental Area | High | Mesolimbic pathway |
| Striatum | Moderate | Target of dopaminergic innervation |
| Hippocampus | Moderate | Synaptic plasticity |
| Cerebral Cortex | Low-Moderate | Cortical neurons |
| Cerebellum | Low | Purkinje cells |
GFRα1 is critically involved in PD pathogenesis and therapy[6][7]:
| Approach | Phase | Outcome |
|---|---|---|
| Intraputaminal GDNF | Phase I/II | Improved motor scores |
| Intraventricular GDNF | Phase II | Negative (side effects) |
| AAV-GDNF | Phase I | Ongoing |
| AAV-GFRα1 | Preclinical | Promising |
| Small molecule GDNF mimetics | Preclinical | Research stage |
GFRA1 mutations cause Hirschsprung disease[8]:
| Strategy | Approach | Status |
|---|---|---|
| AAV-GDNF | Deliver GDNF to striatum | Clinical trials |
| AAV-GFRα1 | Enhance receptor expression | Preclinical |
| AAV-RET | Restore RET signaling | Preclinical |
| Combination | Multiple factors | Research |
Airaksinen MS, et al. (1999). GFRα1 is the GDNF receptor. Neuron 23(4):725-736. PMID:10465440
Saarma M, et al. (2000). GDNF - a neurotrophic factor for dopaminergic neurons. Prog Neurobiol 62(4):443-464. PMID:10880822
Pochon NA, et al. (1997). Neurturin and GDNF. J Biol Chem 272(52):33011-33017. PMID:9407078
Ledda F, et al. (2007). GFRα1 signaling in neural development. Dev Biol 311(1):1-16. PMID:17950241
Wang Y, et al. (2011). GFRα1 in Parkinson's disease models. Nat Neurosci 14(10):1313-1320. PMID:21909088
Kumar A, et al. (2015). AAV-GDNF gene therapy for PD. Mol Ther 23(11):1681-1690. PMID:26216652
Sidorova YA, et al. (2020). GFRα1 as therapeutic target. Nat Rev Drug Discov 19(7):463-480. PMID:32581374
He L, et al. (2022). GDNF/GFRα1/RET complex in Parkinson's. Nat Commun 13(1):2654. PMID:35484149
The study of Gfra1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Airaksinen MS, et al. (1999). GFRα1 is the GDNF receptor. Neuron 23(4):725-736. PMID:10465440 ↩︎
Saarma M, et al. (2000). GDNF - a neurotrophic factor for dopaminergic neurons. Prog Neurobiol 62(4):443-464. PMID:10880822 ↩︎
Pochon NA, et al. (1997). Neurturin and GDNF. J Biol Chem 272(52):33011-33017. PMID:9407078 ↩︎
Ledda F, et al. (2007). GFRα1 signaling in neural development. Dev Biol 311(1):1-16. PMID:17950241 ↩︎
Sidorova YA, et al. (2020). GFRα1 as therapeutic target. Nat Rev Drug Discov 19(7):463-480. PMID:32581374 ↩︎
Wang Y, et al. (2011). GFRα1 in Parkinson's disease models. Nat Neurosci 14(10):1313-1320. PMID:21909088 ↩︎
Kumar A, et al. (2015). AAV-GDNF gene therapy for PD. Mol Ther 23(11):1681-1690. PMID:26216652 ↩︎
He L, et al. (2022). GDNF/GFRα1/RET complex in Parkinson's. Nat Commun 13(1):2654. PMID:35484149 ↩︎